Herpes zoster and postherpetic neuralgia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Herpes zoster (HZ; shingles) results from reactivation of varicella-zoster virus that has been dormant in the spinal and cranial sensory ganglia following primary infection with varicella (chickenpox), usually during childhood. In developed countries more than 95% of the adult population are seropositive for varicella-zoster virus and are therefore at risk of developing HZ. Reactivation can occur at any age, but it is associated with an age-related decline in cell-mediated immunity and therefore occurs more frequently in older adults. Thus, HZ affects up to 25% of individuals during their lifetime, but approximately 50% of those aged 80 years or more. Whilst the disease is rarely life-threatening, it is associated with a number of acute symptoms such as a vesicular rash and pain. Longer-term complications include visual disturbances and postherpetic neuralgia (PHN), which is potentially the most troubling problem of all, and is associated with severe itching and allodynia. These can combine to negatively impact the day-to-day functioning and quality of life of the patient. Hospitalization associated with HZ and PHN is frequent in older individuals and a significant cost to healthcare providers. Current management of HZ with antiviral drugs and analgesics produces reasonable results in younger patients, in whom the disease is usually milder, and is effective against acute pain and skin rash. However, it is much less effective against PHN, which occurs more commonly and more severely in older patients. Once PHN has developed, current treatments offer only limited benefit and adverse effects are common. Management is challenging and often unsatisfactory (<50% of patients gain 50% relief of pain). With the older adult population steadily growing in size, the number of patients presenting with HZ is also likely to increase and this will place a greater burden on healthcare systems. Prevention strategies, such as vaccinating those at greatest risk, may offer the best option for the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Recommendations for the management of herpes zoster
Dworkin, R. H., Johnson, R. W., Breuer, J., Gnann, J. W., Levin, M. J., Backonja, M., Betts, R. F., Gershon, A. A., Haanpää, M. L., McKendrick, M. W., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510206 · Cited by 869
Cited by
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Deer, T. R., Mekhail, N., Provenzano, D., Pope, J., Krames, E., Leong, M., Levy, R. M., Abejon, D., Buchser, E., Burton, A., et al. (2014) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12208 · Cited by 596
Leroux-Roels, I., Leroux-Roels, G., Clement, F., Vandepapelière, P., Vassilev, V., Ledent, E., & Heineman, T. C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis497 · Cited by 147
Turner, N. M., MacRae, J., Nowlan, M. L., McBain, L., Stubbe, M. H., & Dowell, A. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021241 · Cited by 17
“7 Around half of the zoster cases >70 years of age will develop postherpetic neuralgia (PHN).(11) The main rationale for the use of a zoster vaccine is to prevent the long-lasting effects of PHN.”
Background
Metadata
- Authors
- Johnson, R. W.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 9
- Issue
- sup3
- Pages
- 21-26
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2091217595
- Cited by
- 128
- References
- 2
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Herpes zoster and postherpetic neuralgia. https://app.cochat.ai/papers/10.1586/erv.10.30
- The paper
- Johnson, R. W. (2010). Herpes zoster and postherpetic neuralgia. Expert Review of Vaccines. https://doi.org/10.1586/erv.10.30
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.